Category: Spasticity
Objective: To assess pain relief in a large cohort of incoA-treated pts with spasticity-associated pain (SAP) using pooled data from mostly placebo-controlled phase 2/3 studies.
Background: IncobotulinumtoxinA (incoA) has shown pain-relieving benefits in patients (pts) with limb spasticity in individual studies; data from large pt cohorts are lacking.
Method: Pain severity was assessed with the Disability Assessment Scale (DAS; 0–3) in adults with upper limb SAP. A ≥1 point reduction in the DAS pain score from baseline [BL] to 4 weeks was defined as response. Between-treatment group response rates (overall and by BL pain severity – DAS mild, moderate, severe) and the proportion of pts with complete pain relief (DAS pain score=0) at 4 weeks after 1 injection of incoA (total dose ≤400U) or placebo were analyzed using χ2 test. Overall between-group response rate differences were analyzed using logistic regression (presented as odds ratio [OR] and 95% confidence interval [CI]).
Results: 542 (incoA: 413, placebo: 129) pts reported SAP at BL. At 4 weeks, a significantly higher proportion of incoA- vs placebo-treated pts achieved a response (52.1% vs 28.7%; p<0.0001). IncoA-treated pts were more likely to achieve pain response vs placebo-treated pts (OR 2.7 [95% CI:1.6–4.3]; p<0.0001). Irrespective of BL pain severity, significantly higher response rates were observed with incoA vs placebo at 4 weeks (p<0.02 all comparisons). Complete pain relief was achieved by significantly more incoA- vs placebo-treated pts at 4 weeks (26.9% vs 12.4%; p=0.0007).
Conclusion: Pts receiving incoA vs placebo are significantly, by 2.7 times, more likely to achieve reduced upper limb SAP, irrespective of baseline pain severity, at 4 weeks post-injection thus supporting use of incoA in this setting.
To cite this abstract in AMA style:
J. Wissel, A. Camões-Barbosa, G. Comes, M. Althaus, A. Scheschonka, D. Simpson. Pain reduction in adult patients with limb spasticity following a single incobotulinumtoxinA injection: an analysis of pooled data from phase 2 and 3 studies [abstract]. Mov Disord. 2022; 37 (suppl 2). https://www.mdsabstracts.org/abstract/pain-reduction-in-adult-patients-with-limb-spasticity-following-a-single-incobotulinumtoxina-injection-an-analysis-of-pooled-data-from-phase-2-and-3-studies/. Accessed May 15, 2025.« Back to 2022 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/pain-reduction-in-adult-patients-with-limb-spasticity-following-a-single-incobotulinumtoxina-injection-an-analysis-of-pooled-data-from-phase-2-and-3-studies/